Brisbane-based Kira Biotech Pty Ltd. is poised to enter the clinic after raising AU$20 million (US$13.72 million) in series A funding to develop therapies targeting immune system disorders. The round was led by Oneventures, one of Australia's leading venture capital firms with more than AU$330 million in funds under management.

Med-tech firms raising money in public or private financings.

Biopharmas raising money in public or private financings.

Med-tech firms raising money in public or private financings.

Biopharmas raising money in public or private financings.

Biopharmas raising money in public or private financings.

Med-tech firms raising money in public or private financings.

Biopharmas raising money in public or private financings.

BEIJING – After Suzhou, China-based Ascentage Pharma Group International launched a $53 million IPO on the Hong Kong Stock Exchange (HKEX) Monday, Tot Biopharm International Co. Ltd., also from Suzhou, and Sinomab Bioscience Ltd., of Hong Kong, will also debut on the bourse to reap as much as $87 million and $223.1 million, respectively, in the following two weeks.